Developer docs
API playgroundTry for free, no card

Search company profiles

Biorasi

Full company profile

uuid0007oyf

Namestring
Biorasi
Legal namestring
Biorasi, LLC
Websiteurl
biorasi.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Biorasi is a privately held, full-service contract research organization (CRO) founded in 2002 and headquartered in Aventura, Florida, with wholly-owned operating subsidiaries in Germany (Biorasi GmbH) and India (Biorasi Clinical Services Pvt. Ltd.). The company delivers end-to-end clinical trial management services to small biotech and mid-sized biopharma sponsors across neurology, nephrology, dermatology, oncology, and cell therapy therapeutic areas, operating in 48 countries with reach to 65% of the global population. Biorasi has contributed to five FDA approvals over the last seven years and reports 200+ completed global studies and 2,258 initiated trial sites.

The company's service portfolio spans full-service clinical trial management, trial rescue and recovery, data sciences and biometrics, clinical monitoring, safety and pharmacovigilance, AI-powered feasibility, and quality assurance. Core technology assets include the proprietary TALOS project management system and the Beeline sponsor-facing portal, which delivers 15 real-time KPI dashboards covering query trends, site activation, enrollment versus projections, protocol deviations, demographics, and AE/SAE analysis. Strategic technology partnerships with IBM Watson Health (Clinical Development platform), Ryght AI (AI-driven feasibility, site digital twins, agentic copilots), Flatiron Health (EHR-to-EDC integration), and Quotient Sciences (early-phase clinical development, announced October 2025) extend the platform's capabilities.

Biorasi monetizes through custom project-based contracts for complex clinical trials, sold via direct enterprise sales engagement without resellers or distributors. Pricing is bespoke by trial complexity, therapeutic area, geographic scope, and service bundle, with multi-year contract cadence. The company is backed by RLH Equity Partners, which leads its Board of Directors; in March 2026, COO Melissa Alesse was elevated to President while former CEO Chris O'Brien transitioned to the Board, signaling a planned succession under PE ownership.

Short descriptiontext

Biorasi is a privately held, full-service contract research organization founded in 2002, serving small biotech and mid-sized biopharma sponsors with complex clinical trials across neurology, nephrology, dermatology, oncology, and cell therapy in 48 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAventura, United States
HQ citystring
Aventura
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, contract research organization, clinical monitoring, biopharmaceutical research, pharmacovigilance services
Industry5 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization Services
TypeProfessional Services
Description

Full-service CRO providing clinical trial management and execution services to pharmaceutical and biotech sponsors. Services include trial rescue, data sciences, clinical monitoring, safety and pharmacovigilance, feasibility, and quality assurance. Revenue generated through project-based contracts for complex clinical trials across neurology, nephrology, dermatology, oncology, and cell therapy therapeutic areas.

biorasi.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Full-Service CRO Engagement
ModelOtherBilling cadenceMulti-year contract
Notes

Custom project-based pricing for comprehensive clinical trial management. Services can be bundled (full-service strategy) or provided as standalone offerings (clinical monitoring, data sciences, safety, feasibility).

biorasi.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Few & Far Between Podcast
Description

A podcast hosted by Melissa Alesse featuring conversations with biotech leaders and industry experts on drug development innovations.

biorasi.com
+2 more records
Core offering1 text field

Biorasi is a full-service contract research organization (CRO) that manages and executes complex clinical trials for small biotech and mid-sized biopharma sponsors. It delivers end-to-end services — including trial rescue, clinical monitoring, data sciences, safety and pharmacovigilance, feasibility, and quality assurance — powered by its proprietary TALOS project management system and Beeline real-time sponsor portal. The company specializes in neurology, nephrology, dermatology, oncology, and cell therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 5 FDA approvals achieved in the last 7 years
+5 more records
Product overview1 text field

Biorasi is a full-service contract research organization (CRO) providing end-to-end clinical trial services for complex studies. The core offering is built on proprietary TALOS™ project management system enabling speed and agility. Key modules include Trial Rescue & Recovery (for struggling trials), Data Sciences & Biometrics, Clinical Monitoring (with Beeline portal for real-time visibility), Safety & Pharmacovigilance, AI-Powered Feasibility, and Quality Assurance. The company specializes in dermatology, oncology, nephrology, neurology, and cell therapy therapeutic areas. Additional offerings include the Few & Far Between podcast series and strategic partnerships with IBM Watson Health and Ryght AI for enhanced capabilities.

Product and service8 records
1Clinical Trial Management (Full-Service CRO)
CategoryClinical Trial Management Services
Description

End-to-end full-service contract research organization (CRO) offering providing comprehensive clinical trial management and execution from first-in-human to proof-of-concept, powered by the proprietary TALOS project management system, for biotech and biopharma sponsors.

2Trial Rescue & Recovery
CategoryClinical Trial Rescue Services
Description

Swift, strategic intervention service to put faltering clinical trials back on track, including restructuring site oversight, activating new sites, and accelerating patient enrollment, for sponsors with at-risk studies.

3Data Sciences & Biometrics
CategoryData Management and Biometrics Services
Description

Quality data solutions from design to delivery, including statistical analysis, data management, and real-world evidence generation, for sponsors needing clinical biometrics and data science capabilities.

4Clinical Monitoring
CategoryClinical Monitoring Services
Description

Fit-for-purpose clinical monitoring combining advanced analytics, hands-on expertise, therapeutic insight, and site-level relationships, with the Beeline portal providing real-time sponsor visibility.

5Safety & Pharmacovigilance
CategorySafety and Pharmacovigilance Services
Description

End-to-end safety management including 24/7 medical monitoring, AE/SAE case processing, signal detection, and regulatory submissions, using validated safety databases like Oracle Argus.

6AI-Powered Feasibility
CategorySite Feasibility and Patient Recruitment Services
Description

Dynamic site modeling, feasibility outreach, and real-time enrollment forecasting integrating AI data, operational discipline, and patient access insights, featuring AI-driven feasibility via the Ryght AI partnership.

7Quality Assurance
CategoryQuality Assurance and Compliance Services
Description

Quality management services ensuring compliance with GCP standards and regulatory requirements across clinical trials, with documented 100% audit/inspection pass rate across sponsor programs.

8Therapeutic Expertise Services (Dermatology, Oncology, Nephrology, Neurology, Cell Therapy)
CategoryTherapeutic Area Clinical Trial Services
Description

Specialized clinical trial expertise in dermatology, oncology, nephrology, neurology, and cell therapy, organized as dedicated Centers of Excellence with therapeutic-area experts, for sponsors developing therapies in these complex areas.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Strategic partnership to provide integrated early phase clinical trial solutions combining Quotient's expertise in clinical development with Biorasi's global patient recruitment capabilities. The partnership aims to streamline drug development processes from IND to proof-of-concept within first-in-human trials, supporting sponsors with a single-provider model and expanded access to patient networks.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-09-11
Description

Preferred vendor partnership using IBM's Clinical Development (ICD) platform - a single-instance, fully-integrated SaaS clinical data management system. Biorasi reduced database build time by 25% and overall project costs by more than half by leveraging ICD's capabilities. The platform provides 24/7 access to data via single URL from any web-enabled device.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership to bring advanced AI-driven feasibility capabilities including dynamic AI digital twins of global research sites, automated feasibility forms cutting feasibility cycles to under 3 weeks, and agentic copilots for protocol parsing and automated document generation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty CRO focused on rare disease, oncology, and neuroscience for small-to-mid biopharma. Direct peer in therapeutic area, sponsor size, and complex-trial positioning.

TypeDirect peer
Description

PE-backed specialty CRO (acquired by Permira) with strong rare disease and oncology focus. Comparable in scale, therapeutic specialization, and PE-backed growth posture.

TypeRegional player
Description

China-based leading CRO serving biotech and biopharma sponsors. Comparable in clinical trial services but primarily serves Asia-Pacific with different geographic center of gravity.

TypeDirect peer
Description

Mid-to-large full-service CRO focused on complex, scientifically-driven trials for small and mid-sized biopharma sponsors. Highly comparable to Biorasi in therapeutic specialization, sponsor profile, and emphasis on quality execution.

TypeDirect peer
Description

Mid-sized global CRO with therapeutic specialization in neuroscience, cardiometabolic, and rare disease. Directly comparable to Biorasi in scale, therapeutic focus, and biotech/biopharma sponsor base.

TypeBroad incumbent
Description

Global top-tier CRO offering comprehensive clinical and consulting services. Competes with Biorasi in full-service trial management but at vastly larger scale with broader therapeutic and geographic reach.

TypeBroad incumbent
Description

Large full-service CRO with broad therapeutic coverage. Comparable in clinical trial management services but operates at significantly larger scale with broader biopharma sponsor base.

TypeBroad incumbent
Description

Large biopharmaceutical solutions organization (now private under Elliott Investment Management post-take-private). Comparable in full-service CRO offerings and biotech/biopharma sponsor base, but at much larger scale.

TypeDirect peer
Description

Asia-Pacific-headquartered mid-sized CRO with strong biotech/biopharma focus. Comparable in mid-tier scale and biotech sponsor profile, with overlapping geographic and therapeutic focus.

TypeBroad incumbent
Description

Largest global CRO with integrated technology, data, and clinical services. Represents the top end of Biorasi's competitive set, especially in preferred-vendor mega-deals with large biopharma.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biorasi

Contract Research Organization (CRO) Servicesbiorasi.com

Biorasi is a privately held, full-service contract research organization founded in 2002, serving small biotech and mid-sized biopharma sponsors with complex clinical trials across neurology, nephrology, dermatology, oncology, and cell therapy in 48 countries.

What Biorasi does

Biorasi is a privately held, full-service contract research organization (CRO) founded in 2002 and headquartered in Aventura, Florida, with wholly-owned operating subsidiaries in Germany (Biorasi GmbH) and India (Biorasi Clinical Services Pvt. Ltd.). The company delivers end-to-end clinical trial management services to small biotech and mid-sized biopharma sponsors across neurology, nephrology, dermatology, oncology, and cell therapy therapeutic areas, operating in 48 countries with reach to 65% of the global population. Biorasi has contributed to five FDA approvals over the last seven years and reports 200+ completed global studies and 2,258 initiated trial sites.

The company's service portfolio spans full-service clinical trial management, trial rescue and recovery, data sciences and biometrics, clinical monitoring, safety and pharmacovigilance, AI-powered feasibility, and quality assurance. Core technology assets include the proprietary TALOS project management system and the Beeline sponsor-facing portal, which delivers 15 real-time KPI dashboards covering query trends, site activation, enrollment versus projections, protocol deviations, demographics, and AE/SAE analysis. Strategic technology partnerships with IBM Watson Health (Clinical Development platform), Ryght AI (AI-driven feasibility, site digital twins, agentic copilots), Flatiron Health (EHR-to-EDC integration), and Quotient Sciences (early-phase clinical development, announced October 2025) extend the platform's capabilities.

Biorasi monetizes through custom project-based contracts for complex clinical trials, sold via direct enterprise sales engagement without resellers or distributors. Pricing is bespoke by trial complexity, therapeutic area, geographic scope, and service bundle, with multi-year contract cadence. The company is backed by RLH Equity Partners, which leads its Board of Directors; in March 2026, COO Melissa Alesse was elevated to President while former CEO Chris O'Brien transitioned to the Board, signaling a planned succession under PE ownership.

Biorasi firmographics

Firmographics
Name
Biorasi
Legal name
Biorasi, LLC
Website
https://biorasi.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Biorasi is a privately held, full-service contract research organization founded in 2002, serving small biotech and mid-sized biopharma sponsors with complex clinical trials across neurology, nephrology, dermatology, oncology, and cell therapy in 48 countries.
Ownership category
akta.pro rank

Biorasi industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical trial services
  • Contract research organization
  • Clinical monitoring
  • Biopharmaceutical research
  • Pharmacovigilance services

Where Biorasi is headquartered

Location

Headquarters

HQ city
Aventura
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Biorasi business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Organization Services: Full-service CRO providing clinical trial management and execution services to pharmaceutical and biotech sponsors. Services include trial rescue, data sciences, clinical monitoring, safety and pharmacovigilance, feasibility, and quality assurance. Revenue generated through project-based contracts for complex clinical trials across neurology, nephrology, dermatology, oncology, and cell therapy therapeutic areas.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFull-Service CRO Engagement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Biorasi product offering

Product offering

Core offering

Biorasi is a full-service contract research organization (CRO) that manages and executes complex clinical trials for small biotech and mid-sized biopharma sponsors. It delivers end-to-end services — including trial rescue, clinical monitoring, data sciences, safety and pharmacovigilance, feasibility, and quality assurance — powered by its proprietary TALOS project management system and Beeline real-time sponsor portal. The company specializes in neurology, nephrology, dermatology, oncology, and cell therapy.

Product overview

Biorasi is a full-service contract research organization (CRO) providing end-to-end clinical trial services for complex studies. The core offering is built on proprietary TALOS™ project management system enabling speed and agility. Key modules include Trial Rescue & Recovery (for struggling trials), Data Sciences & Biometrics, Clinical Monitoring (with Beeline portal for real-time visibility), Safety & Pharmacovigilance, AI-Powered Feasibility, and Quality Assurance. The company specializes in dermatology, oncology, nephrology, neurology, and cell therapy therapeutic areas. Additional offerings include the Few & Far Between podcast series and strategic partnerships with IBM Watson Health and Ryght AI for enhanced capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Few & Far Between Podcast: A podcast hosted by Melissa Alesse featuring conversations with biotech leaders and industry experts on drug development innovations.
  • Beeline
  • TALOS

Products and services

  • Clinical Trial Management (Full-Service CRO) End-to-end full-service contract research organization (CRO) offering providing comprehensive clinical trial management and execution from first-in-human to proof-of-concept, powered by the proprietary TALOS project management system, for biotech and biopharma sponsors.
  • Trial Rescue & Recovery Swift, strategic intervention service to put faltering clinical trials back on track, including restructuring site oversight, activating new sites, and accelerating patient enrollment, for sponsors with at-risk studies.
  • Data Sciences & Biometrics Quality data solutions from design to delivery, including statistical analysis, data management, and real-world evidence generation, for sponsors needing clinical biometrics and data science capabilities.
  • Clinical Monitoring Fit-for-purpose clinical monitoring combining advanced analytics, hands-on expertise, therapeutic insight, and site-level relationships, with the Beeline portal providing real-time sponsor visibility.
  • Safety & Pharmacovigilance End-to-end safety management including 24/7 medical monitoring, AE/SAE case processing, signal detection, and regulatory submissions, using validated safety databases like Oracle Argus.
  • AI-Powered Feasibility Dynamic site modeling, feasibility outreach, and real-time enrollment forecasting integrating AI data, operational discipline, and patient access insights, featuring AI-driven feasibility via the Ryght AI partnership.
  • Quality Assurance Quality management services ensuring compliance with GCP standards and regulatory requirements across clinical trials, with documented 100% audit/inspection pass rate across sponsor programs.
  • Therapeutic Expertise Services (Dermatology, Oncology, Nephrology, Neurology, Cell Therapy) Specialized clinical trial expertise in dermatology, oncology, nephrology, neurology, and cell therapy, organized as dedicated Centers of Excellence with therapeutic-area experts, for sponsors developing therapies in these complex areas.

Quantifiable outcome

  • 5 FDA approvals achieved in the last 7 years
  • +5 more outcomes

Companies that use Biorasi

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles2 records

Biorasi technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability6 records

Feature5 records

Biorasi partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Quotient SciencescoreStrategic or Co-development Partner · 14 October 2025Strategic partnership to provide integrated early phase clinical trial solutions combining Quotient's expertise in clinical development with Biorasi's global patient recruitment capabilities. The partnership aims to streamline drug development processes from IND to proof-of-concept within first-in-human trials, supporting sponsors with a single-provider model and expanded access to patient networks.
  • IBM Watson HealthcoreTechnology or Integration · 11 September 2020Preferred vendor partnership using IBM's Clinical Development (ICD) platform - a single-instance, fully-integrated SaaS clinical data management system. Biorasi reduced database build time by 25% and overall project costs by more than half by leveraging ICD's capabilities. The platform provides 24/7 access to data via single URL from any web-enabled device.
  • Ryght AIcoreTechnology or IntegrationStrategic partnership to bring advanced AI-driven feasibility capabilities including dynamic AI digital twins of global research sites, automated feasibility forms cutting feasibility cycles to under 3 weeks, and agentic copilots for protocol parsing and automated document generation.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Biorasi competitors and assessment

Company assessment

Direct peers

  • Premier Research: Specialty CRO focused on rare disease, oncology, and neuroscience for small-to-mid biopharma. Direct peer in therapeutic area, sponsor size, and complex-trial positioning.
  • Ergomed: PE-backed specialty CRO (acquired by Permira) with strong rare disease and oncology focus. Comparable in scale, therapeutic specialization, and PE-backed growth posture.
  • Medpace: Mid-to-large full-service CRO focused on complex, scientifically-driven trials for small and mid-sized biopharma sponsors. Highly comparable to Biorasi in therapeutic specialization, sponsor profile, and emphasis on quality execution.
  • Worldwide Clinical Trials: Mid-sized global CRO with therapeutic specialization in neuroscience, cardiometabolic, and rare disease. Directly comparable to Biorasi in scale, therapeutic focus, and biotech/biopharma sponsor base.
  • Novotech: Asia-Pacific-headquartered mid-sized CRO with strong biotech/biopharma focus. Comparable in mid-tier scale and biotech sponsor profile, with overlapping geographic and therapeutic focus.

Regional players

  • Tigermed: China-based leading CRO serving biotech and biopharma sponsors. Comparable in clinical trial services but primarily serves Asia-Pacific with different geographic center of gravity.

Broad incumbents

  • ICON plc: Global top-tier CRO offering comprehensive clinical and consulting services. Competes with Biorasi in full-service trial management but at vastly larger scale with broader therapeutic and geographic reach.
  • Parexel: Large full-service CRO with broad therapeutic coverage. Comparable in clinical trial management services but operates at significantly larger scale with broader biopharma sponsor base.
  • Syneos Health: Large biopharmaceutical solutions organization (now private under Elliott Investment Management post-take-private). Comparable in full-service CRO offerings and biotech/biopharma sponsor base, but at much larger scale.
  • IQVIA: Largest global CRO with integrated technology, data, and clinical services. Represents the top end of Biorasi's competitive set, especially in preferred-vendor mega-deals with large biopharma.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Biorasi social profiles

Digital presence

Biorasi compliance and trust

Trust signal

Compliance9 records

Biorasi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biorasi leadership team

Management profile

Number of profiles

Profiles13 records

Biorasi subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Biorasi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biorasi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biorasi

What does Biorasi do?

Biorasi is a full-service contract research organization (CRO) that manages and executes complex clinical trials for small biotech and mid-sized biopharma sponsors. It delivers end-to-end services — including trial rescue, clinical monitoring, data sciences, safety and pharmacovigilance, feasibility, and quality assurance — powered by its proprietary TALOS project management system and Beeline real-time sponsor portal. The company specializes in neurology, nephrology, dermatology, oncology, and cell therapy.

Is Biorasi a public or private company?

Biorasi is a private company. It is classified as private equity controlled and is currently operating.

When was Biorasi founded?

Biorasi was founded in 2002. It employs 101 to 250 people.

Where is Biorasi based?

Biorasi is headquartered in Aventura, United States, in the North America region.

How does Biorasi make money?

One revenue line is on record: contract Research Organization Services.

Who are Biorasi's main competitors?

Direct peers on record are Premier Research, Ergomed, Medpace, Worldwide Clinical Trials and Novotech. Tigermed is listed as a regional player. Broad incumbents are ICON plc, Parexel, Syneos Health and IQVIA.

Does Biorasi have an API?

No public API is recorded for Biorasi.

What industry is Biorasi in?

Biorasi's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ThedermdigestAOB Pharma Taps Biorasi to Execute Phase 2b Acne Trial; Company Maintains Phase 3 AD Trial TimelineAOB Pharma has partnered with Clinical Research Organization Biorasi to execute a Phase 2b clinical trial for its B244 topical formulation in patients with moderate-to-severe acne. The company intends to submit the new protocol to the FDA by July 10th, aiming to accelerate data readouts and potentially fast-track future regulatory milestones for this indication.AijournAOB Pharma and Biorasi to Partner to run Phase 2b in Moderate to Severe AcneAOB Pharma (AOBiome), a clinical-stage biotechnology company, announced a partnership with Biorasi, a clinical research organization, to launch a Phase 2b clinical trial for B244 in moderate to severe acne vulgaris, with enrollment of 176 patients across 13 clinical sites beginning this fall. The company plans to submit its new Phase 2b protocol to the FDA under its existing IND on July 10th, advancing the trial ahead of schedule while maintaining its atopic dermatitis global Phase 3 timeline. B244 has shown encouraging signals in earlier-phase studies and produces nitric oxide to target anti-inflammatory activity, sebum production, and C. acnes.PR NewswireAOB Pharma and Biorasi to Partner to run Phase 2b in Moderate to Severe AcneAOB Pharma (AOBiome) has partnered with clinical research organization Biorasi to launch a Phase 2b clinical trial evaluating its B244 topical treatment in patients with moderate to severe acne vulgaris, based on encouraging earlier-phase data. The trial is expected to enroll 176 patients across 13 clinical sites, with the company planning to submit its Phase 2b protocol to the FDA under an existing IND on July 10th. Acne affects an estimated 50 million Americans annually, and the company believes B244's novel anti-inflammatory mechanism targeting sebum production and C. acnes could address significant unmet need in patients who respond inadequately to existing treatments.MorningstarAnnouncement from Biorasi, LLC: Melissa Alesse Appointed President as Chris O'Brien Steps into Board of Directors RoleBiorasi, a Miami-based contract research organization, announced that Chief Executive Officer Chris O'Brien will step down and transition to the company's Board of Directors, with Chief Operating Officer Melissa Alesse appointed as President effective immediately. The leadership change, endorsed by Biorasi's Board led by RLH Equity Partners, is positioned as a planned succession reflecting the company's commitment to continuity and operational excellence. Alesse, who has been central to recent operational transformations in delivery, quality, and customer experience, will also host the company's Few & Far Between podcast.PR NewswireQuotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-conceptQuotient Sciences and Biorasi announced a strategic partnership to deliver fully integrated early phase clinical trial solutions for biotech and pharma sponsors. The partnership combines Quotient Sciences' clinical pharmacology expertise, with facilities in Miami and Nottingham comprising 230 beds, with Biorasi's global patient recruitment network spanning dermatology, neurology, nephrology, and other specialty therapeutic areas. The unified model offers sponsors a single contracting approach and streamlined regulatory submissions to reduce outsourcing complexity and accelerate development timelines from first-in-human studies to patient proof-of-concept.PR NewswireQuotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-conceptQuotient Sciences, a drug development and manufacturing accelerator, and Biorasi, a global clinical research organization (CRO), announced a strategic partnership to deliver fully integrated early phase clinical trial solutions for biotech and pharma sponsors. The partnership combines Quotient Sciences' clinical pharmacology expertise (230-bed facilities in Miami, USA and Nottingham, UK) with Biorasi's global patient recruitment network spanning multiple therapeutic areas, providing a single provider model from first-in-human Phase I/IIa studies to patient proof-of-concept. The CEOs of both companies framed the deal as reducing outsourcing complexity and accelerating development timelines by up to 12 months.FinancialContent Business PageBiorasi Unveils New Website to Drive Sponsor Success with Biotech-Centric Strategies and Modular CRO SolutionsBiorasi relaunched its website to highlight modular clinical trial solutions and AI-powered tools for biotech sponsors. The site emphasizes sponsor-centric strategy, with over 200 global studies, five FDA approvals, and $150M+ in recovered rescue studies. It also promotes accelerated startup modules and flexible data sciences.MorningstarRyght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma SponsorsRyght AI announced a partnership with CRO Biorasi to integrate its AI-powered feasibility platform into Biorasi's services. The platform uses dynamic digital twins of research sites to compress feasibility timelines from months to under three weeks. The collaboration aims to improve site selection accuracy and reduce trial delays for biotech and biopharma sponsors.HIT ConsultantRyght AI Announces Partnership with Biorasi to Transform Feasibility Accuracy in Clinical TrialsRyght AI announced a partnership with Biorasi to bring AI-driven feasibility capabilities to clinical trials. The collaboration uses Ryght AI's SOC Type 2-compliant digital twin platform to improve site selection and recruitment forecasts. Biorasi will deploy it across dermatology, oncology, neurology, and nephrology studies.